COPENHAGEN, March 15, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biotechnology company dedicated to the innovation and development of peptide drugs, reports substantial growth in revenue and other operational income, a positive net result, cash preservation and important progress in its drug pipeline and business activities for the twelve month period from 1 January to 31 December 2011.
